FDA Takes More Conservative Approach To Quantifying Oncologic Benefit

FDA seems to be taking a more conservative approach to quantifying oncologics' benefits, based on agency comments during a Sept. 13-14 meeting of its Oncologic Drugs Advisory Committee

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet